Cell Based Assays Congress 2014 Europe

SL51

Background Info

Cell Based Assays Congress 2014 Europe

Cell-Based Assays 2014 Europe explores the latest thinking and techniques in this growing topic. Cell-based assays are becoming more important as companies realize their usage can significantly reduce the amount of clinical candidates failing to progress through the pipeline, as the assays demonstrably prove leads have a clinical effect. This event covers many topics, which are of vital scientific importance, such as ion channel assays, 3D assays, GPCR, as well as stem cell assays. Moreover, the event also looks at non-scientific areas of concern, such as post-analytics, quality control, and outsourcing, making this event a more rounded conference than other events on the same topic. As R&D budgets are squeezed and costs have to be accounted for, researchers have to be aware of other considerations in their assays, and this conference looks at these as well.

Book now and join us for an exciting two days of interactive and innovative discussions about the potentials of CBA and what are currently on offer and demands in the market today. This is a great opportunity to network with professionals in the field and enjoy learning about new developments in technologies, techniques, methods and detection involved in the CBA process.

Who Should ATTEND?
Presidents, Chief Executives, Chief Scientific Officers, Chief Operating Officers, Vice Presidents, Senior Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project /Team Leaders in:
• High-Throughput / High – Content Screening Operations
• GPCR / Kinases / Molecular Pharmacology
• Stem Cell Technologies & Platforms
• Bioanalytical Development
• Toxicology and Safety Testing
• Pharmacovigilance and Safety Testing
• In Vitro Sciences
• Drug Delivery
• Drug Discovery / Validation
• Drug Development
• Antibody Discovery
• ADMET
• Pre-clinical Development
• Medical Chemistry
• Compound Profiling
• Cellular Imaging
• Lead Generation
• Pharmacodynamics
• Pharmacokinetics
• External/Contract Research
• Medical Chemistry
• Chemistry and Bioapplications
• Global Research and Development
• Business Development
• Investment and Venture Capital
• Neuroscience – Preclinical & Biomarkers
• Neurodegenerative and Neurological Diseases

Key Speakers


Sofia Rebelo

Sofia Rebelo, Research member at iBET/ITQB-UNL, Portugal

Sofia Rebelo is a research member at the Animal Cell Technology (ACT) Unit of the Instituto de Biologia Experimental e Tecnológica (iBET) and Instituto de Tecnologia Química e Biológica (ITQB-UNL), where she integrates the team involved in the development of in-vitro models for pre-clinical research for toxicological applications and neural and cancer research. With a background in biological sciences and bioengineering systems, she has been developing 3D-based tools for prediction of hepatic metabolism and toxicity, working with primary cultures and hepatic cell lines.


Sheraz Gul

Sheraz Gul, Vice President and Head of Biology, European ScreeningPort, Germany

Sheraz Gul is Vice President and Head of Biology at European ScreeningPort, Hamburg, Germany where he manages the assay development and screening of academic targets. Prior to this, he worked for GlaxoSmithKline for 7 years where he developed biochemical and cellular assays for High Throughput Screening as well as Hit characterization. He has a PhD and 5 years post-doctoral research experience all from the University of London. He has co-authored numerous papers, book chapters and the Enzyme Assays: Essential Data Handbook. In addition, he has been appointed to the editorial boards of the European Pharmaceutical Review and International Drug Discovery.


Rob Howes

Dr. Rob Howes, Associate Director, HTS, Antibody Discovery and Protein Engineering, MedImmune

Rob completed his PhD at the MRC Laboratory of Molecular Biology understanding signalling pathways in Drosphila followed by post-doctoral positions at Stanford University, USA and Cambridge University. In 2001 he joined Vernalis, a UK-based drug development company where he was in charge of the Screening group working across several disease areas including Oncology and Neuroscience. In 2008 he helped start Horizon Discovery, a translational genomics company that uses the adeno-associated virus (AAV) gene targeting technology to generate isogenic human cell lines. At Horizon he also established their Centres of Excellence program to enable academic groups with the gene targeting technology which included such groups as the National Institutes of Health, Cambridge University and Yale University. He recently joined MedImmune, the global biologics division of AstraZeneca leading the Screening team based in Cambridge, UK.


Gary Allenby

Gary Allenby, Chief Scientific Officer, Aurelia Bioscience

After completing a Ph.D. in reproductive toxicology from Edinburgh University in the U.K., I post-doc’ed at Hoffmann La Roche in the U.S.A, working on the physiology and pharmacology of retinoid biology and developing retinoids as candidate drugs. I returned to the U.K. as a senior scientist in Lead Generation at Glaxo Wellcome, developing cell-based assays for CNS – pain targets and working with vendors to automate/validate new technologies for screening purposes. In 2000 I joined a department of assay develoment and high throughput screening at AstraZeneca, developing assays and working on targets for respiratory and inflammatory disease. Following the closure of the AstraZeneca site in Loughborough in 2011, I became the founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organisation specialising in the development of cell-based assays for compound and biologics screening. Our unique selling point is the development of phenotypic assays for screening purposes using human primary cells were possible.


Professor Paul French

Professor Paul French – Photonics Group, Physics Department, Imperial College London

Professor Paul French, Head of Photonics Group, was a Royal Society University Research Fellow at Imperial from 1989 and joined the academic staff in 1994. He has been a Visiting Professor at the University of New Mexico and a Consultant at AT&T Bell Laboratories. His research has evolved from ultrafast dye and solid-state laser physics to biomedical optics with a particular emphasis on FLIM for applications in molecular cell biology, drug discovery and clinical diagnosis. His current portfolio includes the development and application of multidimensional fluorescence imaging for microscopy, endoscopy and tomography. He is a Fellow of the Institute of Physics, the European Physical Society and the Optical Society of America.


Dr. David Hay

Dr. David Hay – Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh

Dr. David Hay is a Principal Investigator at the University of Edinburgh’s MRC Centre for Regenerative Medicine. David has worked in the field of stem cell biology and differentiation over the last decade. David’s work has highlighted the important role that biology and chemistry play in generating high fidelity human liver cells from pluripotent stem cells. The impact of this work has led to a number of publications, successful grant applications, a spin-out company, FibromEd, and regular appearances at high profile international conferences.


Sheraz Gul

Dr Sheraz Gul, CChem MRSC, CSi, European ScreeningPort GmbH

Sheraz Gul is Vice President and Head of Biology at European ScreeningPort, Hamburg, Germany where he manages the assay development and screening of academic targets. Prior to this, he worked for GlaxoSmithKline for 7 years where he developed biochemical and cellular assays for High Throughput Screening as well as Hit characterization. He has a PhD and 5 years post-doctoral research experience all from the University of London. He has co-authored numerous papers, book chapters and the Enzyme Assays: Essential Data Handbook. In addition, he has been appointed to the editorial boards of the European Pharmaceutical Review and International Drug Discovery.


Grant Cameron

Grant Cameron, PhD – RAFT Development Director, Tap Biosystems

Grant Cameron brings 20 years experience from a broad range of life science markets including biomarkers, proteomics, automation, cell biology and analytical chemistry. Subsequent to running an application support team he became more focussed on the commercial and business development aspects of new product and technology introduction with Genomic Solutions, NextGen Sciences and now with 3D cell culture at TAP Biosystems. The commercial experience is supported by a PhD in biochemistry from Newcastle University followed by four years of post-doctoral research at Cambridge University. Grant joined TAP Biosystems as the Development Director for the RAFT 3D cell culture system in June 2010.


Paul Andrews

Dr. Paul Andrews, Director, Stem Cell Solutions Ltd.

Paul gained his first degree in Biochemistry and a PhD in Molecular Biology from the University of Sheffield, and after a year in infertility research moved to the Biochemistry Department at the University of Dundee, Scotland, to pursue his interest in cell signaling and the cell cycle were he worked for several years in Michael Stark’s laboratory understanding the essential roles of type-1 protein phosphatase using budding yeast as a model system. Paul then went on to develop the growing deconvolution microscopy facility in Dundee for two years before returning to the bench to make important contributions to our understanding of Aurora B Protein Kinase and its role in mitosis, in the lab of Jason Swedlow. He was subsequently recruited to the Drug Discovery Unit in Dundee in 2007 to lead the ITI Stem Cell Technology Screening Group during which time he established the Unit’s high content screening capabilities. Paul next moved to work at the Swedish stem cell company Cellartis AB, where he was team leader responsible for the development of cell-therapy grade media and supported small molecule screening in the Novo Nordisk-funded stem cells-to-beta cells programme. In 2012 Paul established Stem Cell Solutions Ltd, a consultancy service specializing in the uses of stem cells and phenotypic drug discovery.


Robert E Zoubek

Dr. Robert E. Zoubek, Senior Consultant, Granzer Regulatory Consulting and Services

Robert E. Zoubek, PhD, joined Granzer Regulatory Consulting & Services in October 2013. Robert supports our clients in all questions concerning drug development, manufacturing and quality control for biologics and biosimilars. As expert he is frequently invited to give talks and lead workshops on international conferences.
Robert has more than 10 years of experience in the development of pharmaceuticals. Until he joined Granzer Regulatory Consulting & Services, Robert worked in several positions at Formycon (former Scil Technology) and GlycoForm in the UK.
As Director Scientific Affairs he led Formycon´s drug product development and analytical services. He advised numerous clients on their development strategies, planned and accompanied their projects through the different development stages. Before that, Robert was Head of Protein Characterisation & Preformulation and Manager Quality Operations. In those positions he supervised Formycon´s Quality Control and was responsible for the GMP compliant organisation of the certified laboratories.
He also worked at GlycoForm in Abingdon, UK. As research biologist, he contributed to the development of Biobetters based on GlycoForm´s expertise to chemically synthesize complex glycan structures.


Rob Howes

Dr. Rob Howes, Associate Director, HTS, Antibody Discovery and Protein Engineering, MedImmune

Rob completed his PhD at the MRC Laboratory of Molecular Biology understanding signalling pathways in Drosphila followed by post-doctoral positions at Stanford University, USA and Cambridge University. In 2001 he joined Vernalis, a UK-based drug development company where he was in charge of the Screening group working across several disease areas including Oncology and Neuroscience. In 2008 he helped start Horizon Discovery, a translational genomics company that uses the adeno-associated virus (AAV) gene targeting technology to generate isogenic human cell lines. At Horizon he also established their Centres of Excellence program to enable academic groups with the gene targeting technology which included such groups as the National Institutes of Health, Cambridge University and Yale University. He recently joined MedImmune, the global biologics division of AstraZeneca leading the Screening team based in Cambridge, UK.


Farnaz Fallah-Arani

Farnaz Fallah-Arani

Farnaz is currently a group leader in the Dept of pharmacology at UCB Celltech in Slough, UK and has experience in pre-clinical research and drug discovery of biologics and small molecules. Farnaz is an Immunologist by training and has a strong interest in the immunobiology of autoimmune and inflammatory disease.


Dabrowski

Michael Dabrowski, PhD, CEO Pelago Biosciences

Michael Dabrowski, PhD, CEO Pelago Bioscience has 15 years of pre-clinical Drug Discovery experience from several therapy areas at Novo Nordisk and AstraZeneca with a strong delivery record of science, project, people and budget management. Dr Dabrowski has vast experience as a project leader, manager responsible for screening and assay technology development as well as strategic disease area portfolio management and execution. Throughout his career a special focus has been on enabling technologies. Therefore his role in implementing the patent pending CETSA™ method for Target Engagement determinations in Drug Discovery disciplines is a particular exiting development.


Rozbeh Jafari

Dr. Rozbeh Jafari, PhD, Post Doc, Karolinska Institute

Rozbeh Jafari, PhD, is a biomedical scientist and did his PhD at Karlstad University in the field of Cancer Immunotherapy using antibody fragments targeting keratins in tumors and multicellular tumor spheroids. He joined Prof. Pär Nordlunds group at the department of Medical Biochemistry and Biophysics at Karolinska Institutet as a Postdoc in 2011 where they developed and validated a method for evaluating drug binding at the target level inside cells and tissues, the Cellular Thermal Shift Assay (CETSA™).


Day 1

Day 1 – 27th February 2014

08:00-09:00 – Registration & Networking Coffee

09:30-09:40 – Chairman’s welcome

Dr. Paul Andrews, Director, Stem Cell Solutions Ltd.

09:40-10:20 – Latest update and Regulatory requirement for cell-based assays

  • Understand why cell-based assays are becoming standard practise
  • Getting regulatory approval: what’s needed to become compliant
  • Metting GMP requirements
  • What does the future hold? As more complex techniques become more commonplace, can we expect more regulation?

Dr. Robert Zoubek, Senior Consultant, Granzer Regulatory Consulting & Services

10:20-11:00 – Towards complex human 3D models for drug discovery

  • Controlled bioreactor cultures for feeding high throughput systems
  • Microencapsulation as tool for mimicking the microenvironment in stirred systems
  • Recapitulation of liver phsiology in cell lines and primary cultures of human hepatocytes

Sofia Rebelo, Research Member, iBET/ITQB – UNL, Portugal

11:00-11:40 – Morning Networking Refreshments – Exhibitors Lounge

11:40-12:20 – The role of cell – based kinase assay in drug discovery

  • Evaluating the popularity of kinase enzymes for drug discovery
  • Reviewing the range of kinase assays in drug discovery
  • Assessing the advantages the cell – based kinase assays offer in improving the chances of identifying kinase inhibitors from small molecule screening campaigns whose activities are more likely to translate in the drug discovery cascade

Sheraz Gul, Vice President, Head of Biology, European Screening Port

12:20-13:00 – Leveraging Cell – Based Assays for use in Drug discovery

  • Technologies used to examine cell function in drug discovery
  • Our on – going works in cell-based biology
  • Perspective on the future of Phenotypic versus target based screening

Gary Allenby, Chief Scientific Officer, Aurelia Bioscience

13:00-14:00 – Networking Lunch Break

14:00-14:40 – Cell based assays in biologics drug discovery

  • Challenges of cell – based assays in biologics drug discovery
  • Evolution of cell-based assays with examples from MedImmune drug discovery projects
  • Which assay formats will we be using in the future?

Dr. Rob Howes, Associate Director, HTS, Antibody Discovery and Protein Engineering, MedImmune

14:40-15:20 – Using immunological in vitro and in vivo model systems to determine target specific Mode of Action

  • Specific immunological human and mouse in vitro assay and their corresponding in vitro models will be discussed
  • How can this models be used to determine functionality and potency of different molecules
  • Translatability of these findings into the clinic

Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB

15:20-16:00 – Afternoon Networking – Refreshments – Exhibitors Lounge

16:00-16:40 – The Importance of pluripotent stem cells in drug discovery: from toxicology to cell therapy

  • Introduction to hES/hiPS cells: current and potential uses in drug discovery
  • How do we create the cell types industry needs? What are the hurdles?
  • Recreating cell fate decisions in vitro using small molecules and growth factors
  • Case studies of phenotypic screening using hES cells: cell survival & pluripotency
  • Where will pluripotent stem cells go next?

Dr. Paul Andrews, Director, Stem Cell Solutions Ltd.

16:40-17:00 – Chairman Summary & comments – End of day one

Dr. Paul Andrews, Director, Stem Cell Solutions Ltd.

Day 2


Day 2 – 18th February 2014

09:00-09:30 – Registration & Networking Coffee

09:30-09:40 – Chairman’s opening comments

Grant Cameron, PhD – RAFT Development Director, Tap Biosystems

09:40-10:20 – Cellular Thermal Shift Assays: A method for monitoring drug target engagement in cells and tissues

  • Evaluating drug transport, activation and distribution
  • Assessing drug specificity and off-target interactions
  • Profiling different protein states

Dr. Rozbeh Jafari, PhD, Biomedical Scientist, Karolinska Institue

10:20 – 11:00 – The use of 3D cell culture in oncology research

  • Where and how does a 3D cell culture technique add to your research
  • Which analytical techniques are applicable, in particular when cells have formed higher order structures such as tumoroids?
  • The application of cell signaling and protein phosphorylation assays in 3D oncology

Grant Cameron, PhD – RAFT Development Director, Tap Biosystems

11:00-11:40 – Networking Morning Refreshments – Exhibitors Lounge

11:40-12:20 – Cell Based assays in the preclinical Drug Discovery value chain

  • Pros and cons of cell based assays in pre-clinical Drug Discovery projects
  • Translation of potency and efficacy measures
  • Using CETSA™ for Target Engagement determination and Lead/Candidate selection

Dr. Michael Dabrowski, PhD, CEO, Pelago Biosciences

12:20-13:00 – PANEL: The future for cell-based assays; what new targets are coming to the fore, what new techniques are being explored

  • Dr. Michael Dabrowski, PhD, CEO, Pelago Biosciences
  • Grant Cameron, PhDRAFT Development Director, Tap Biosystems
  • Dr. David Hay – Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh

 

13:20-14:00 – Networking Lunch Break

14:00-14:40 – Flourescence lifetime imaging for HCA from Automated multiwell Plate Assays to disease model

  • Automated (optically sectioning) fluorescence lifetime imaging for assays based on FRET readouts of protein interactions
  • Application of automated FLIM plate reader to assay HIV Gag protein aggregation with Z’ > 0.5
  • Application of automated FLIM plate reader to identifying binding partners and quantifying interactions using FRET
  • Application of automated FLIM plate reader to cellular auto flourescence for label-free readouts of changes in cellular metabolism

Prof. Paul FrenchProfessor of Physics, Head of Photonics Group, Physics Department, Imperial College London

14:40-15:20 – Developing High Fidelity Hepatotoxicity Models from Pluripotent Stem Cells

  • Stem cells offer an unlimited source of hepaotcytes for human drug screening
  • Stem cell derived hepatocytes exhibit equivalence to gold standard models
  • Stem cell derived hepatocytes have an important role to play in human drug discovery

Dr. David Hay – Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh

15:20-1530 – Chairman’s Summary & closing comments – End of conference

Grant Cameron, PhD – RAFT Development Director, Tap Biosystems

Sponsors & Exhibitors


axol

AXOL

Axol is a fresh and exciting biotech company founded to fulfil the unmet demand for high quality iPS cell-derived, clinically relevant cells for use in biomedical research and discovery. We are applying cutting-edge stem cell technologies to generate high quality human neural stem cells and neurons. Cerebral cortical neurons are implicated in numerous neurological diseases including Alzheimer’s, autism, epilepsy, traumatic brain injury and stroke. Despite growing support for research in these areas, high quality human in vitro cell models for cortical neurophysiology have been unavailable until now. Axol has led the launch of their technology with a focus on providing both healthy and Alzheimer’s disease relevant human neurons derived from iPS cells. 

We are providing researchers with an affordable, easily accessible, in vitro human system to complement their existing studies of cortical development, function and diseases, while helping them to avoid potential ethical challenges faced when considering the use of embryonic stem cells. Our technology provides a platform for developing or testing novel therapeutic interventions and understanding the disease pathologies more thoroughly.
www.axolbio.com


axionAxion Biosytem’s Multielectrode Array (MEA) systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives. Axion are represented in the UK by World Precision Instruments.
Visit Website

Partners


Media Partners

PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE’s more than 25,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. For further information please visit: www.pharmavoice.com

Biocompare is the most comprehensive, in-depth, and objective website for life science product information. Thousands of scientists use Biocompare daily to quickly find the right product for their experiments rather than looking through multiple print catalogs. Visit www.biocompare.com to find the products you need, stay informed of new technologies, read product reviews, watch product videos, and keep up-to-date on life science news. For further information please visit: www.biocompare.com

European Life Science is the premier journal devoted to presenting outstanding research and researchers within the life science fields. For further information please visit: www.life-science.se

SelectScience.net is the leading online product and application publication for laboratory scientists featuring the latest news, application articles, videos, product directory and product reviews. Membership is fast, free and provides access to all of the SelectScience services. SelectScience.tv is a unique video news channel for laboratory application and product information. For further information please visit: www.selectscience.net

InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com

PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision- makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. For further information please visit: www.futurepharmaus.com